News
REGMF
9.81
NaN%
--
RemeGen Sets Board Meeting to Approve First-Quarter 2026 Results
TipRanks · 1h ago
RemeGen Receives US$650 Million Upfront from AbbVie for RC148 Global Rights
TipRanks · 1d ago
RemeGen Wins Fifth China Approval for Flagship ADC in Urothelial Cancer
TipRanks · 5d ago
CICC Reaffirms Their Buy Rating on RemeGen Co. Ltd. Class H (9995)
TipRanks · 04/03 05:16
RemeGen Co. Ltd. Class H (9995) Gets a Buy from J.P. Morgan
TipRanks · 04/02 00:35
RemeGen Wins NMPA Nod to Start Clinical Trial of Bispecific ADC RC288
TipRanks · 04/01 17:54
RemeGen Co. Ltd. Class H (9995) Gets a Buy from BOCOM International Holdings Company
TipRanks · 04/01 05:36
RemeGen Co. Ltd. Class H (9995) Gets a Buy from Bank of China
TipRanks · 04/01 05:25
RemeGen Boosts 2025 Revenue as Telitacicept Wins New Approvals and NRDL Access
TipRanks · 03/27 16:56
RemeGen Wins Fourth NMPA Approval for Disitamab Vedotin in HER2-Low Breast Cancer
TipRanks · 03/23 11:38
RemeGen Schedules March 27 Board Meeting to Approve 2025 Annual Results
TipRanks · 03/17 08:46
RemeGen Swings to Profit on Strong 2025 Revenue Growth
TipRanks · 02/27 12:02
BOCOM International Holdings Company Sticks to Its Buy Rating for RemeGen Co. Ltd. Class H (9995)
TipRanks · 02/04 05:07
RemeGen Forecasts 2025 Profit Turnaround on Surging Drug Sales and Global Licensing Deal
TipRanks · 01/30 12:12
BOCOM International Holdings Company Sticks to Their Buy Rating for RemeGen Co. Ltd. Class H (9995)
TipRanks · 01/21 05:35
RemeGen Co. Ltd. Class H (9995) was upgraded to a Buy Rating at Zhongtai Securities
TipRanks · 01/21 05:35
RemeGen Completes RMB20 Million A-Share Buyback for Future Equity Incentives
TipRanks · 01/21 00:09
RemeGen Raises Share Buyback Price Cap to Enable A‑Share Repurchase Plan
TipRanks · 01/15 14:20
RemeGen Signs Up to US$5.6 Billion Global Licensing Deal with AbbVie for Cancer Drug RC148
TipRanks · 01/12 13:08
RemeGen Co., Ltd. Announces A Share Repurchase Plan to Boost Employee Incentives
TipRanks · 12/15/2025 15:12
More
Webull provides a variety of real-time REGMF stock news. You can receive the latest news about Remegen through multiple platforms. This information may help you make smarter investment decisions.
About REGMF
RemeGen Co Ltd is a China-based company principally engaged in biopharmaceutical research, biopharmaceutical service, biopharmaceutical production and sale. The Company focuses on therapeutic antibody drugs such as antibody-drug conjugates (ADC), antibody fusion proteins, monoclonal antibodies and bispecific antibodies. The Company’s main products include telitacicept, disitamab vedotin, RC28-E and others. The Company's products are mainly used to treat major diseases such as autoimmune diseases, oncology and ophthalmology. The Company mainly operates its businesses in the domestic and overseas markets.